ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of One-Time Pregnenolone, Dehydroepiandrosterone (DHEA), or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers (DHEA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00900900
Recruitment Status : Completed
First Posted : May 13, 2009
Last Update Posted : September 21, 2012
Sponsor:
Information provided by (Responsible Party):
Jed E. Rose, Duke University

Brief Summary:
This study will evaluate the potential therapeutic value of two neurosteroid treatments (DHEA and pregnenolone) in the treatment of tobacco withdrawal symptoms. This will include assessing whether these agents relieve craving for cigarettes elicited by exposure to a mildly stressful cognitive task. Pregnenolone (400 mg orally), DHEA (400 mg orally) and placebo will be administered one at each of the three sessions in a randomized order.

Condition or disease Intervention/treatment Phase
Substance Withdrawal Syndrome Dietary Supplement: dehydroepiandrosterone (DHEA) Dietary Supplement: pregnenolone Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of One-Time Pregnenolone, DHEA, Or Placebo Administration On Withdrawal Symptoms, Mood, Craving And Cigarette Evaluation Ratings In Male Smokers
Study Start Date : July 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Dehydroepiandrosterone (DHEA) Dietary Supplement: dehydroepiandrosterone (DHEA)
one-time 400mg oral dose of DHEA
Experimental: Pregnenolone Dietary Supplement: pregnenolone
one-time 400mg oral dose of pregnenolone
Placebo Comparator: Placebo Drug: Placebo
one-time dose oral dose



Primary Outcome Measures :
  1. The administration of DHEA or pregnenolone will reduce smoking withdrawal symptoms. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. The administration of DHEA or pregnenolone will reduce the subjective rewarding effects of nicotine inhaled in cigarette smoke. [ Time Frame: 6 months ]
  2. The administration of DHEA or pregnenolone will reduce stress-induced changes in mood and craving for cigarettes. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. male;
  2. 18-65 years old;
  3. smoked an average of at least 10 cigarettes per day for three cumulative or continuous years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5 mg nicotine;
  4. afternoon expired carbon monoxide reading of at least 10 ppm;
  5. in general good health, based on physical examination, EKG serum chemistries, CBC and urinalysis.

Exclusion Criteria:

  1. Participants must not have uncontrolled hypertension (systolic >140 mm Hg, diastolic >95 mm Hg)
  2. hypotension (systolic <90 mm Hg, diastolic <60 mm Hg);
  3. coronary heart disease;
  4. heart attack;
  5. cardiac rhythm disorder (irregular heart rhythm);
  6. chest pains (unless history, exam, and EKG clearly indicate a non-cardiac source);
  7. cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
  8. liver or kidney disorder (except kidney stones, gallstones);
  9. gastrointestinal problems or disease other than gastroesophageal reflux,
  10. heartburn, or irritable bowel syndrome;
  11. ulcers within the past 6 months;
  12. lung disorder (including but not limited to COPD, emphysema, and asthma);
  13. brain abnormality (including but not limited to, stroke, brain tumor, seizure disorder);
  14. history of fainting;
  15. problems giving blood samples;
  16. diabetes;
  17. current cancer or treatment for cancer in the past 6 months (except basal or squamous cell skin cancer);
  18. other major medical condition;
  19. major depression, panic disorder, anxiety, bipolar disorder, schizophrenia, risk of suicide, or substance dependence other than nicotine dependence;
  20. subjects who endorse suicidal ideation on the MINI abridged;
  21. alcohol or drugs abuse;
  22. reported use of illicit drugs within the past 30 days, or if the drug screen is positive;
  23. reported use of smokeless tobacco (chewing tobacco, snuff), cigars, pipes, or nicotine replacement therapy; testosterone replacement therapy, DHEA or Pregnenolone; experimental (investigational) drugs; psychiatric medications (including antidepressants, anti-anxiety agents. anti-psychotics), sleep aids, medications that increase DHEA and/or DHEA-S concentrations (including, but not limited to: diltiazem, benfluorex, amlodipine, alprazolam, danazol, metformin, nitrendipine and retinol), or any other medications that are known to affect smoking (e.g. clonidine, muscle relaxants, opiate pain medications) within the past 2 weeks.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00900900


Locations
United States, North Carolina
Duke Center for Nicotine & Smoking Cessation Research
Durham, North Carolina, United States, 27705
Duke Center for Nicotine & Smoking Cessation Research
Raleigh, North Carolina, United States, 27609
Sponsors and Collaborators
Jed E. Rose
Investigators
Principal Investigator: Jed E Rose, Ph.D. Duke University
Principal Investigator: Christine Marx, M.D. Duke University

Responsible Party: Jed E. Rose, Professor Department of Psychiatry and Behavorial Sciences, Duke University
ClinicalTrials.gov Identifier: NCT00900900     History of Changes
Other Study ID Numbers: Pro00008225
First Posted: May 13, 2009    Key Record Dates
Last Update Posted: September 21, 2012
Last Verified: September 2012

Keywords provided by Jed E. Rose, Duke University:
Cigarette Smokers
DHEA
dehydroepiandrosterone
pregnenolone
Nicotine withdrawal symptoms

Additional relevant MeSH terms:
Substance Withdrawal Syndrome
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Dehydroepiandrosterone
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs